Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
作者： E A Faylona , P J Loehrer , R Ansari , A B Sandler , R Gonin
DOI: 10.1200/JCO.1995.13.5.1209
关键词: Combination chemotherapy 、 Surgery 、 Etoposide 、 Medicine 、 Nitrogen mustard 、 Interim analysis 、 Phases of clinical research 、 Ifosfamide 、 Lung cancer 、 Gastroenterology 、 Chemotherapy 、 Internal medicine
摘要: PURPOSEThe study was undertaken to determine the activity and toxicity of oral etoposide (VP-16), ifosfamide, cisplatin combination chemotherapy for previously treated, recurrent small-cell lung cancer (SCLC).PATIENTS AND METHODSIn this phase II trial, 46 patients were enrolled receive VP-16, 37.5 mg/m2/d 21 days, ifosfamide 1.2 g/m2/d 4 20 with courses repeated every 28 days. Response, survival, data then noted.RESULTSForty-two assessable response, toxicity. Thirty-six 42 had received prior plus VP-16. The first 22 VP-16 but subsequent 14 days after an interim analysis showed marked myelosuppression. Twenty-three (55%) objective six complete responses (CRs; 14%), 17 partial (PRs; 40%). median progression-free survival time weeks (ran...
sci-hub.se 参考文章(11)
Lawrence H. Einhorn, John McClean, Kenneth Pennington, Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Seminars in Oncology. ,vol. 17, pp. 32- 35 ,(1990) , 10.5555/URI:PII:009377549090069F
Feld R, Evans Wk, Yau Jc, MacCormick R, Shepherd Fa, Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer treatment reports. ,vol. 71, pp. 941- 944 ,(1987)
N Murray, P Coy, J L Pater, I Hodson, A Arnold, B C Zee, D Payne, E C Kostashuk, W K Evans, P Dixon, Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 11, pp. 336- 344 ,(1993) , 10.1200/JCO.1993.11.2.336
M L Slevin, P I Clark, S P Joel, S Malik, R J Osborne, W M Gregory, D G Lowe, R H Reznek, P F Wrigley, A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1333- 1340 ,(1989) , 10.1200/JCO.1989.7.9.1333
ROBERT M. O'Bryan, John J. Crowley, Paik N. Kim, Robert B. Epstein, Barbara Neilan, Charles A. Coltman, Walter J. Stuckey, Richard Pazdur, Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study Cancer. ,vol. 65, pp. 856- 860 ,(1990) , 10.1002/1097-0142(19900215)65:4<856::AID-CNCR2820650404>3.0.CO;2-6
Giuseppe Giaccone, Second line chemotherapy in small cell lung cancer Lung Cancer. ,vol. 5, pp. 207- 213 ,(1989) , 10.1016/0169-5002(89)90169-4
B J Roth, D H Johnson, L H Einhorn, L P Schacter, N C Cherng, H J Cohen, J Crawford, J A Randolph, J L Goodlow, G O Broun, Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group Journal of Clinical Oncology. ,vol. 10, pp. 282- 291 ,(1992) , 10.1200/JCO.1992.10.2.282
W K Evans, D Osoba, R Feld, F A Shepherd, M J Bazos, G DeBoer, Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. Journal of Clinical Oncology. ,vol. 3, pp. 65- 71 ,(1985) , 10.1200/JCO.1985.3.1.65
D H Johnson, F A Greco, J Strupp, K R Hande, J D Hainsworth, Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. Journal of Clinical Oncology. ,vol. 8, pp. 1613- 1617 ,(1990) , 10.1200/JCO.1990.8.10.1613
William G. Cochran, Some Methods for Strengthening the Common χ 2 Tests Bioethics. ,vol. 10, pp. 417- ,(1954) , 10.2307/3001616